[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201507305SA - Pharmaceutical combination drug - Google Patents

Pharmaceutical combination drug

Info

Publication number
SG11201507305SA
SG11201507305SA SG11201507305SA SG11201507305SA SG11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA
Authority
SG
Singapore
Prior art keywords
pharmaceutical combination
combination drug
drug
pharmaceutical
combination
Prior art date
Application number
SG11201507305SA
Inventor
Jayhyuk Myung
Kyung Wan Nam
Cheol Woo Lee
Ju Won Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of SG11201507305SA publication Critical patent/SG11201507305SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201507305SA 2013-03-14 2014-03-14 Pharmaceutical combination drug SG11201507305SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130027114 2013-03-14
PCT/KR2014/002178 WO2014142607A1 (en) 2013-03-14 2014-03-14 Pharmaceutical combination drug

Publications (1)

Publication Number Publication Date
SG11201507305SA true SG11201507305SA (en) 2015-10-29

Family

ID=51537139

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507305SA SG11201507305SA (en) 2013-03-14 2014-03-14 Pharmaceutical combination drug

Country Status (16)

Country Link
US (1) US9592233B2 (en)
EP (1) EP2974719B1 (en)
JP (1) JP6068765B2 (en)
KR (1) KR101502031B1 (en)
CN (2) CN105120845A (en)
AU (1) AU2014230182B2 (en)
CA (1) CA2905686C (en)
ES (1) ES2747098T3 (en)
MX (1) MX368148B (en)
MY (1) MY174729A (en)
PH (1) PH12015502108A1 (en)
RU (1) RU2639818C2 (en)
SA (1) SA515361123B1 (en)
SG (1) SG11201507305SA (en)
WO (1) WO2014142607A1 (en)
ZA (1) ZA201507576B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545268B1 (en) 2015-02-05 2015-08-20 보령제약 주식회사 Tablet and method of preparing the same
WO2017091041A1 (en) * 2015-11-26 2017-06-01 보령제약 주식회사 Novel salt of fimasartan
CN105784867B (en) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 Make the purposes of reference standard for analyzing HPLC method and these impurity of the Fimasartan in relation to substance
KR102078691B1 (en) * 2017-11-30 2020-02-19 보령제약 주식회사 Solid dispersion comprising Fimasartan
KR102201396B1 (en) * 2017-11-30 2021-01-11 보령제약 주식회사 Phamaceutical composition comprising Fimasartan
KR101997652B1 (en) * 2018-01-22 2019-07-08 보령제약 주식회사 Pharmaceutical formulation
KR101992400B1 (en) * 2018-04-30 2019-06-24 보령제약 주식회사 Pharmaceutical formulation
KR102022694B1 (en) * 2019-02-20 2019-09-18 주식회사 네비팜 Pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
CN101461799B (en) * 2008-12-31 2011-06-29 苏州中化药品工业有限公司 Stable pravastatin medicament composition and preparation method thereof
ES2364011B1 (en) 2009-11-20 2013-01-24 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
KR101058284B1 (en) 2010-01-22 2011-08-22 보령제약 주식회사 Novel Process for the Preparation of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide
CN104610164B (en) 2010-01-21 2018-03-16 保宁制药株式会社 2 (base of 2 normal-butyl, 4 hydroxyl, 6 methylpyrimidine 5) N, the preparation method of N dimethyl acetamides
KR20110097168A (en) 2010-02-24 2011-08-31 근화제약주식회사 New pharmaceutical composition for treatment of hyperlipidemia
KR101248804B1 (en) * 2010-05-14 2013-03-29 한미사이언스 주식회사 BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN
CN101972260B (en) * 2010-11-24 2012-05-02 天津市汉康医药生物技术有限公司 Rosuvastatin calcium oral pharmaceutical composition
CN102485228B (en) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 Pharmaceutical composition and purpose thereof
SG194162A1 (en) * 2011-04-12 2013-11-29 Boryung Pharm Antihypertensive pharmaceutical composition
KR101168136B1 (en) 2011-08-08 2012-07-24 보령제약 주식회사 Antihypertensive pharmaceutical composition

Also Published As

Publication number Publication date
KR101502031B1 (en) 2015-03-12
AU2014230182B2 (en) 2016-12-22
JP2016512234A (en) 2016-04-25
AU2014230182A1 (en) 2015-09-24
MY174729A (en) 2020-05-11
EP2974719B1 (en) 2019-08-28
EP2974719A4 (en) 2016-08-03
EP2974719A1 (en) 2016-01-20
US20160022679A1 (en) 2016-01-28
CN105120845A (en) 2015-12-02
US9592233B2 (en) 2017-03-14
MX2015011988A (en) 2015-12-01
RU2015142255A (en) 2017-04-26
JP6068765B2 (en) 2017-01-25
SA515361123B1 (en) 2018-04-29
CA2905686A1 (en) 2014-09-18
ES2747098T3 (en) 2020-03-10
PH12015502108B1 (en) 2016-01-18
PH12015502108A1 (en) 2016-01-18
ZA201507576B (en) 2017-01-25
MX368148B (en) 2019-09-20
RU2639818C2 (en) 2017-12-22
BR112015022000A8 (en) 2023-01-17
BR112015022000A2 (en) 2017-07-18
WO2014142607A1 (en) 2014-09-18
KR20140113512A (en) 2014-09-24
CN110123771A (en) 2019-08-16
CA2905686C (en) 2017-06-27

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
HRP20180684T1 (en) Drug combination
GB201306610D0 (en) Pharmaceutical compounds
ZA201507576B (en) Pharmaceutical combination drug
HK1223833A1 (en) Pharmaceutical dosage forms
ZA201600027B (en) Pharmaceutical preparation
ZA201506465B (en) Pharmaceutical preparation
GB201316662D0 (en) Pharmaceutical Combination
GB201310496D0 (en) Pharmaceutical combinations
GB201301723D0 (en) Pharmaceutical combinations
GB201308780D0 (en) Pharmaceutical compounds